@ProfManchanda profile picture
Prof Ranjit Manchanda @ProfManchanda

Prof Wolfson Institute of Population Health, QMUL; Consultant Gynae-Oncologist Barts Health NHS Trust; Hon Prof LSHTM; Precision Prevention in Women’s Cancers

Joined November 2019
  • Tweets 853
  • Following 479
  • Followers 1,063
75 Photos and videos
Prof Ranjit Manchanda retweeted
ISRCTN: the UK's Clinical Study Registry@ISRCTN
Mar 21
A population-based digital study offering people testing for cancer genes, to identify people at increased risk of cancer so they can take steps to prevent it or detect it early. The PROTECT-C Study registered at #ISRCTN by @ProfManchanda isrctn.com/ISRCTN17289436 #clinicaltrials
PROTECT-C is a research study offering genetic testing to identify people with inherited changes that increase the risk of breast, ovarian, bowel, or womb cancer, regardless of personal or family history. These cancers make up half of all cancers in women, and a proportion are linked to cancer genes that can be managed through NHS screening or preventive options. Current NHS testing criteria miss many people with genetic changes, meaning most remain unaware of their risk. The study will offer testing to 5000 people for nine cancer genes and provide personalised breast and ovarian cancer risk estimates using the CANRISK algorithm. It will assess how many people choose testing, how many genetic changes are found, how many would be missed by standard criteria, and how women respond to personalised risk information. The study will also evaluate user experiences, decision making, uptake of screening or prevention, and NHS affordability.

ALT PROTECT-C is a research study offering genetic testing to identify people with inherited changes that increase the risk of breast, ovarian, bowel, or womb cancer, regardless of personal or family history. These cancers make up half of all cancers in women, and a proportion are linked to cancer genes that can be managed through NHS screening or preventive options. Current NHS testing criteria miss many people with genetic changes, meaning most remain unaware of their risk. The study will offer testing to 5000 people for nine cancer genes and provide personalised breast and ovarian cancer risk estimates using the CANRISK algorithm. It will assess how many people choose testing, how many genetic changes are found, how many would be missed by standard criteria, and how women respond to personalised risk information. The study will also evaluate user experiences, decision making, uptake of screening or prevention, and NHS affordability.

1
1
6
990
eur01.safelinks.protection.o… Good to see the coverage of the NHS JBRCA programme in the JC, highlighting its importance, outreach and benefit. Thx to the huge number of community and professional stakeholders who have supported it. thx to NHSE for the continued support.

EXCLUSIVE: NHS will restart life-saving ‘Jewish cancer gene’ tests - The Jewish Chronicle

Programme testing for BRCA mutation to resume next year after successful launch results, Health Secretary tells JC

thejc.com
2
2
4
147
more replies
@QMUL @QMBCI @QMUL_WIPH @wpp_wiph @eveappeal @OvarianCancerUK @TargetOvarian @Ovacome @BreastCancerNow @PreventBC
1
1
1
106
@
71
Prof Ranjit Manchanda retweeted
Women's Precision Prevention@wpp_wiph
15 Dec 2025
A great time was had by the #WPP_team at our 2025 Christmas party! There have been many wonderful achievement this year; with PhDs, clinical fellowships, Grants, publications and much more to celebrate! Many thanks to Ranjit Manchanda and to Vic White for organising the party.
1
2
84
Good to see our paper finally out Important implications for guidelines and clinical practice This can shorten the diagnostic pathway @eveappeal @BAGPGynPath @BGCS_org @EngageEsgo @ESGO_society @Ovacome @TargetOvarian @OvarianCancerUK @ENYGO_official @ovarcome @IGCSociety
Women's Precision Prevention@wpp_wiph
15 Dec 2025
Our paper ‘Consent model for tumour genetic testing in ovarian cancer’ shows strong support for reflex tumour genetic testing. Most patients, physicians, and charity representatives favoured testing without explicit consent, alongside an opt-out option. tandfonline.com/doi/full/10.…
1
3
4
574
@QMUL @QMBCI @QMUL_WIPH @wpp_wiph
77
Well done Priyanka Onwards and upwards
Women's Precision Prevention@wpp_wiph
15 Dec 2025
Congratulations to our WPP member Priyanka Deshmukh on being awarded PPI grant of £966 from the QMUL Centre for Public Engagement. This PPI work will help inform the design of a future project ‘LEGACY – Lynch Evaluation for Genetic Analysis and Cascade testing in Years past’.
83
Prof Ranjit Manchanda retweeted
The British Assoc of Gynaecological Pathology
@BAGPGynPath
17 Dec 2025
Please join us for our monthly webinar on Wed 17th December at 3 pm UK time. This month's topic is a session on 'New Entities Identified Through Referral Practice' with Prof Glenn McCluggage. Free to register @ thebagp.org/events/list/ #PathTwitter #GynPath #Gynaepath
6
10
1,307
Prof Ranjit Manchanda retweeted
Women's Precision Prevention@wpp_wiph
6 Oct 2025
Replying to @ProfManchanda
@ProfManchanda speaks at the 9th European Tumour Hereditary Group meeting held in Heidelberg in September. He had a keynote presentation on population screening strategies and implications of the PROTECTOR study and presented abstracts of findings from our PRESCORES study.
2
4
91
mdpi-res.com/d_attachment/ca… Great to see our paper out on PPOSSUM score for predicting morbidity in Ovarian cancer cytoreductive surgery. We show it is a poor predictor and should not be used.

1
3
2
123
New validated and accurate model(s) are necessary for predicting surgical morbidity in women undergoing cytoreductive ovarian cancer surgery. @QMUL_WIPH @QMUL_WIPH_CPDD @BGCS_org @BAGPGynPath @ESGO_society @Ovacome @TargetOvarian @OvarianCancerUK @eveappeal @wpp_wiph
1
69
jamanetwork.com/journals/jam… Great to see our paper on Risk Reducing Early Salpingectomy out in JAMA Network Open. We describe our study design for extension of PROTECTOR to address the issue of ovarian cancer risk reduction from RRES.

Estimands for Effectiveness of Early Salpingectomy to Reduce Ovarian Cancer Risk

This comparative effectiveness research study considers how to define clinical effectiveness from prospective cohort studies of women undergoing early salpingectomy with delayed oophortectomy vs...

jamanetwork.com
1
2
4
144
Our estimand and design differs from other ongoing clinical effectiveness studies/trials. PROTECTOR aims to recruit another 1250 high risk women over the next 4 years. Looking forward to work with all our collaborators and stake holders in the coming years.
2
3
58
@QMUL @NHSBartsHealth @QMUL_WIPH @QMUL_WIPH_CPDD @wpp_wiph @BAGPGynPath @BGCS_org @eveappeal @OvarianCancerUK @TargetOvarian @OvCancerDay @Ovacome @ovarcome @Barts_Charity @RosetreesT @IGCSociety @EngageEsgo @ESGO_society @ENYGO_official @BRCAchatter
2
80
Prof Ranjit Manchanda retweeted
Julia Hippisley-Cox@JuliaHCox
29 Jul 2025
NEW 3-Year Postdoc Position We’re hiring a postdoc to join a new, interdisciplinary NIHR programme focused on the design-led development and evaluation of patient-centred risk communication tools for medicine use before & during pregnancy. @NIHRresearch qmul-jobs.tal.net/vx/mobile-…
2
7
693
bartshealth.nhs.uk/jobs/#!/j… We have advertised for a Clinical Research Fellow to work in our Clinical Academic Team @wpp_wiph @NHSBartsHealth We run a number of studies in precision prevention of Women’s cancers wpprevention.org/ Come and join our team Please RT

1
6
8
1,706
@QMUL_WIPH @QMBCI @BGCS_org @ENYGO_official @ESGO_society @IGCSociety @BgcsFellows @eveappeal
2
143
Delighted to host the @eveappeal team today at @wpp_wiph Charterhouse sq @QMUL_WIPH Fantastic interaction with @athenalamnisos1 , VasJames, Ian Jacobs and Christine Ekechi @QMUL @NHSBartsHealth @QMBCI
4
11
368
Load more